# PRESS RELEASE 2011

## Similar remission results shown between once-daily 4g dose and twice-daily 2g doses of mesalazine (PENTASA®) in active ulcerative colitis

Results of a new study presented today at the United European Gastroenterology Week (UEGW) congress in Stockholm demonstrate…

## Ferring Pharmaceuticals acquires Cytokine PharmaSciences Inc.

Ferring Pharmaceuticals (Ferring) announced today that it has completed the purchase of Cytokine PharmaSciences Inc. (CPSI) and its…

## The untold impact of childhood bedwetting in later life

New data, presented today at the International Continence Society (ICS) congress in Glasgow, suggest that bedwetting…

## New research reveals night-time toilet trips are not a trivial problem

New data, presented at the International Continence Society (ICS) Congress, highlight the significant detrimental impact of nocturia…

## New data demonstrating long-term benefits of FIRMAGON® (degarelix) for advanced hormone-dependant prostate cancer published in The Journal of Urology

New data, published in the September issue of The Journal of Urology, showed that long-term use of FIRMAGON®…

## MEGASET Study demonstrated effectiveness and tolerability of MENOPUR® after ICSI in GnRH antagonist cycles

New data presented today at the European Society of Human Reproduction and Embryology (ESHRE) meeting, demonstrated the efficacy…

## Ongoing extension study results provide further evidence for first-line use of FIRMAGON® (degarelix) in advanced prostate cancer

Recent data from the ongoing five-year FIRMAGON® (degarelix) extension study (CS21a) has demonstrated the long term efficacy and tolerability of…

## SMC Announces Acceptance of Degarelix (FIRMAGON®▼) for use within NHS Scotland

Today’s decision by the Scottish Medicines Consortium (SMC) to accept the use of FIRMAGON…